Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia

Cardiovascular Drugs and Therapy

Volumn 10, Issue 2, 1996, Pages 159-166

  Fujiki, Akira ^a   Tani, Masanao ^a   Yoshida, Shigeki ^a   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Adverse effects; Atrioventricular reentrant tachycardia; Cibenzoline; Disopyramide; Pilsicainide; Procainamide

Indexed keywords

ANTIARRHYTHMIC AGENT; CIBENZOLINE; DISOPYRAMIDE; PILSICAINIDE; PROCAINAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ELECTROSTIMULATION; FEMALE; HEART ACCESSORY CONDUCTION PATHWAY; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; REENTRY TACHYCARDIA;

ADOLESCENT; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; DISOPYRAMIDE; ELECTROPHYSIOLOGY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; IMIDAZOLES; LIDOCAINE; MALE; MIDDLE AGED; PROCAINAMIDE; TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 0029998415     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00823594     Document Type: Article

References (11)

1. Kang PS, Gomes JAC, El-Sherif N. Procainamide in the induction and perpetuation of ventricular tachycardia in man. PACE 1982;5:311-322.
2. Au PK, Bhandari AK, Bream R, Schreck D, Siddiqi R, Rahimtoola SH. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia. J Am Coll Cardiol 1987;9:389-397.
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-410.
4. Neuss H, Buss J, Schlepper M, et al. Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. Eur Heart J 1983;4: 347-353.
5. Kerr CR, Prystowsky EN, Smith WM, Cook L, Gallagher JJ. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome. Circulation 1982;65:869-878.
6. Eldar M, Ruder MA, Dovis JC, et al. Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome. PACE 1986;9:652-659.
7. Fujiki A, Mizumaki K, Tani M, Yoshida S, Sasayama S. Electrophysiologic effects and efficacy of cibenzoline in patients with supraventricular tachycardia. J Cardiovasc Pharmacol 1992;20:375-379.
8. Cockrell JL, Scheinman MM, Titus C, et al. Safety and efficacy of oral flecainicle therapy in patients with atrioventricular re-entrant tachycardia. Ann Intern Med 1991;114: 189-194.
9. Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979;301: 1080-1085.
10. Akhtar M, Lehmann MH, Denker ST, Mahmud R, Tchou P, Jazayeri M. Electrophysiologic mechanisms of orthodromic tachycardia initiation during ventricular pacing in the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1987; 9:89-100.
11. Kuck KH, Schluter M, Geiger M, Siebels J, Duckeck W. Radiofrequency current catheter ablation of accessory atrioventricular pathways. Lancet 1991;337:1557-1561.